Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass.--()--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria.

The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia’s lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to CKD in non-dialysis patients and is in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. For more information on Akebia, please visit www.akebia.com.

Contacts

Investors:

Akebia Therapeutics, Inc.
Nicole P. Jones, +1-617-871-1210
Senior Director, Investor Relations and Corporate Communications
njones@akebia.com

Media:

Argot Partners
Eliza Schleifstein, +1-917-763-8106
Eliza@argotpartners.com

Recent Stories

RSS feed for Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.